271 related articles for article (PubMed ID: 30604598)
1. Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials.
Kang YM; Cho YK; Lee J; Lee SE; Lee WJ; Park JY; Kim YJ; Jung CH; Nauck MA
Diabetes Metab J; 2019 Aug; 43(4):410-421. PubMed ID: 30604598
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of glucagon-like peptide-1 receptor agonists on heart rate.
Lorenz M; Lawson F; Owens D; Raccah D; Roy-Duval C; Lehmann A; Perfetti R; Blonde L
Cardiovasc Diabetol; 2017 Jan; 16(1):6. PubMed ID: 28086882
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression.
Rivera FB; Lumbang GNO; Gaid DRM; Cruz LLA; Magalong JV; Bantayan NRB; Lara-Breitinger KM; Gulati M; Bakris G
Diabetes Obes Metab; 2024 Jun; 26(6):2209-2228. PubMed ID: 38505997
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes.
Trujillo J
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):43-60. PubMed ID: 32910487
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy.
Drab SR
Curr Diabetes Rev; 2016; 12(4):403-413. PubMed ID: 26694823
[TBL] [Abstract][Full Text] [Related]
6. Managing the multifaceted nature of type 2 diabetes using once-weekly injectable GLP-1 receptor agonist therapy.
Bzowyckyj A
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):7-16. PubMed ID: 32910488
[TBL] [Abstract][Full Text] [Related]
7. Are the cardiovascular properties of GLP-1 receptor agonists differentially modulated by sulfonylureas? Insights from post-hoc analysis of EXSCEL.
Gooding KM; Stevens S; Lokhnygina Y; Giczewska A; Shore AC; Holman RR
Diabetes Res Clin Pract; 2024 Jun; 212():111685. PubMed ID: 38670496
[TBL] [Abstract][Full Text] [Related]
8. Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis.
Fang L; Li J; Zeng H; Liu J
Prim Care Diabetes; 2024 Jun; 18(3):268-276. PubMed ID: 38555202
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
Abdul-Ghani M; DeFronzo RA; Del Prato S; Chilton R; Singh R; Ryder REJ
Diabetes Care; 2017 Jul; 40(7):813-820. PubMed ID: 28637886
[TBL] [Abstract][Full Text] [Related]
10. Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study.
Anthony MS; Aroda VR; Parlett LE; Djebarri L; Berreghis S; Calingaert B; Beachler DC; Crowe CL; Johannes CB; Juhaeri J; Lanes S; Pan C; Rothman KJ; Saltus CW; Walsh KE
Diabetes Care; 2024 Apr; 47(4):712-719. PubMed ID: 38363873
[TBL] [Abstract][Full Text] [Related]
11. Allelic variant in the glucagon-like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: A pilot pharmacogenetics study.
Chedid V; Vijayvargiya P; Carlson P; Van Malderen K; Acosta A; Zinsmeister A; Camilleri M
Neurogastroenterol Motil; 2018 Jul; 30(7):e13313. PubMed ID: 29488276
[TBL] [Abstract][Full Text] [Related]
12. Cross-sectional, case-control and longitudinal associations between exposure to glucagon-like peptide-1 receptor agonists and the dispensing of antidepressants.
Almeida OP; Fong Z; Hill Almeida LM; Sanfilippo FM; Page A; Etherton-Beer C
Diabetes Obes Metab; 2024 Jul; 26(7):2925-2932. PubMed ID: 38650544
[TBL] [Abstract][Full Text] [Related]
13. The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis.
Abdelmalek MF; Harrison SA; Sanyal AJ
Diabetes Obes Metab; 2024 Jun; 26(6):2001-2016. PubMed ID: 38511418
[TBL] [Abstract][Full Text] [Related]
14. Effects of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) on Cardiac Structure and Function: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
Wong SY; Lee ARYB; Sia AHJ; Wo YJ; Teo YH; Teo YN; Syn NL; Ong CC; Teo LL; Yeo TC; Poh KK; Kong WK; Wong RC; Sia CH
Cardiovasc Drugs Ther; 2024 Apr; 38(2):371-389. PubMed ID: 35819544
[TBL] [Abstract][Full Text] [Related]
15. Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis.
Guirguis A; Chiappini S; Papanti P GD; Vickers-Smith R; Harris D; Corkery JM; Arillotta D; Floresta G; Martinotti G; Schifano F
Eur Neuropsychopharmacol; 2024 May; 82():82-91. PubMed ID: 38508100
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity.
Jensterle M; Janež A
Horm Res Paediatr; 2023; 96(6):599-608. PubMed ID: 34852347
[TBL] [Abstract][Full Text] [Related]
17. Occurrence of Gastrointestinal Adverse Events Upon GLP-1 Receptor Agonist Initiation With Concomitant Metformin Use: A Post Hoc Analysis of LEADER, STEP 2, SUSTAIN-6, and PIONEER 6.
Klein KR; Clemmensen KKB; Fong E; Olsen S; Abrahamsen T; Lingvay I
Diabetes Care; 2024 Feb; 47(2):280-284. PubMed ID: 38048543
[TBL] [Abstract][Full Text] [Related]
18. GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: an updated systematic review and meta-analysis.
Villaschi A; Ferrante G; Cannata F; Pini D; Pagnesi M; Corrada E; Reimers B; Mehran R; Federici M; Savarese G; Metra M; Condorelli G; Stefanini GG; Chiarito M
Clin Res Cardiol; 2024 Jun; 113(6):898-909. PubMed ID: 38252145
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-Like Peptide 1 (GLP-1) Receptor Variants and Glycemic Response to Liraglutide: A Pharmacogenetics Study in Iranian People with Type 2 Diabetes Mellitus.
Eghbali M; Alaei-Shahmiri F; Hashemi-Madani N; Emami Z; Mostafavi L; Malek M; Khamseh ME
Adv Ther; 2024 Feb; 41(2):826-836. PubMed ID: 38172377
[TBL] [Abstract][Full Text] [Related]
20. GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes.
Del Olmo-Garcia MI; Merino-Torres JF
J Diabetes Res; 2018; 2018():4020492. PubMed ID: 29805980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]